Caregiving burdens are a substantial concern in the clinical care of persons with neurodegenerative disorders. In the Ontario Neurodegenerative Disease Research Initiative, we used the Zarit's Burden Interview (ZBI) to examine: (1) the types of burdens captured by the ZBI in a cross‐disorder sample of neurodegenerative conditions (2) whether there are categorical or disorder‐specific effects on caregiving burdens, and (3) which demographic, clinical, and cognitive measures are related to burden(s) in neurodegenerative disorders?
Methods/Design N= 504 participants and their study partners (e.g., family, friends) across: Alzheimer's disease/mild cognitive impairment (AD/MCI; n= 120), Parkinson's disease (PD; n= 136), amyotrophic lateral sclerosis (ALS; n= 38), frontotemporal dementia (FTD; n= 53), and cerebrovascular disease (CVD; n= 157). Study partners provided information about themselves, and information about the clinical participants (e.g., activities of daily living (ADL)). We used Correspondence Analysis to identify types of caregiving concerns in the ZBI. We then identified relationships between those concerns and demographic and clinical measures, and a cognitive battery. Results
We found three components in the ZBI. The first was “overall burden” and was (1) strongly related to increased neuropsychiatric symptoms (NPI severity
r= 0.586, NPI distress r= 0.587) and decreased independence in ADL (instrumental ADLs r= −0.566, basic ADLs r= −0.43), (2) moderately related to cognition (MoCA r= −0.268), and (3) showed little‐to‐no differences between disorders. The second and third components together showed four types of caregiving concerns: current care of the person with the neurodegenerative disease, future care of the person with the neurodegenerative disease, personal concerns of study partners, and social concerns of study partners. Conclusions
Our results suggest that the experience of caregiving in neurodegenerative and cerebrovascular diseases is individualized and is not defined by diagnostic categories. Our findings highlight the importance of targeting ADL and neuropsychiatric symptoms with caregiver‐personalized solutions.